All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 all comers - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results LIFESAVER, 2021 2.00 [0.16; 24.66]
RECOVERY, 2022 0.87 [0.77; 0.98]
Tang X, 2020 0.98 [0.93; 1.02]
0.94 [0.85 ; 1.03 ] LIFESAVER, 2021, RECOVERY, 2022, Tang X, 2020 3 42% 8,254 moderate not evaluable death or transfer to ICUdetailed results BACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88]
0.97 [0.50 ; 1.88 ] BACC Bay Tocilizumab Trial, 2020 1 0% 242 NA not evaluable deathsdetailed results BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62]
LIFESAVER, 2021 2.00 [0.16; 24.66]
RECOVERY, 2022 0.87 [0.77; 0.98]
Tang X, 2020 0.98 [0.93; 1.02]
0.95 [0.87 ; 1.03 ] BACC Bay Tocilizumab Trial, 2020, LIFESAVER, 2021, RECOVERY, 2022, Tang X, 2020 4 23% 8,496 moderate not evaluable clinical deteriorationdetailed results BACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09]
Tang X, 2020 1.00 [0.13; 7.45]
1.10 [0.60 ; 2.01 ] BACC Bay Tocilizumab Trial, 2020, Tang X, 2020 2 0% 328 low not evaluable clinical improvementdetailed results BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41]
Tang X, 2020 1.04 [0.67; 1.62]
1.05 [0.83 ; 1.34 ] BACC Bay Tocilizumab Trial, 2020, Tang X, 2020 2 0% 328 low not evaluable clinical improvement (14-day)detailed results Tang X, 2020 1.33 [0.57; 3.11]
1.33 [0.57 ; 3.11 ] Tang X, 2020 1 0% 86 NA not evaluable clinical improvement (time to event analysis only)detailed results Tang X, 2020 1.04 [0.67; 1.62]
1.04 [0.67 ; 1.62 ] Tang X, 2020 1 0% 86 NA not evaluable death or ventilationdetailed results BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81]
NCT04310228-FAVI (Zhao), 2020 3.60 [0.13; 102.66]
RECOVERY, 2022 0.90 [0.81; 0.99]
0.90 [0.81 ; 0.99 ] BACC Bay Tocilizumab Trial, 2020, NCT04310228-FAVI (Zhao), 2020, RECOVERY, 2022 3 0% 8,159 moderate not evaluable mechanical ventilationdetailed results RECOVERY, 2022 0.87 [0.74; 1.02]
0.87 [0.74 ; 1.02 ] RECOVERY, 2022 1 0% 7,905 NA not evaluable radiologic improvement (14-day)detailed results NCT04310228-FAVI (Zhao), 2020 0.32 [0.06; 1.63]
0.32 [0.06 ; 1.63 ] NCT04310228-FAVI (Zhao), 2020 1 0% NA not evaluable viral clearance detailed results Tang X, 2020 1.78 [1.06; 3.00]
1.78 [1.06 ; 3.00 ] Tang X, 2020 1 0% 86 NA not evaluable viral clearance (time to event analysis only)detailed results Tang X, 2020 1.78 [1.06; 3.00]
1.78 [1.06 ; 3.00 ] Tang X, 2020 1 0% 86 NA not evaluable ICU admissiondetailed results Tang X, 2020 1.00 [0.13; 7.45]
1.00 [0.13 ; 7.45 ] Tang X, 2020 1 0% 86 NA not evaluable serious adverse eventsdetailed results BACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53]
1.21 [0.58 ; 2.53 ] BACC Bay Tocilizumab Trial, 2020 1 0% 242 NA not evaluable adverse eventsdetailed results NCT04310228-FAVI (Zhao), 2020 0.60 [0.05; 6.80]
0.60 [0.05 ; 6.80 ] NCT04310228-FAVI (Zhao), 2020 1 0% 12 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 01:10 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 94
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290